Cost-effectiveness of Low-density Lipoprotein Cholesterol Level–Guided Statin Treatment in Patients With Borderline Cardiovascular Risk
Authors:
Open Access
- 1 October 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 4 (10) , 969-977
Abstract
Hydroxymethylglutaryl–coenzyme A reductase inhibitors (statins) reduce low-density lipoprotein cholesterol (LDL-C) levels and are a cornerstone of primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD).1-5 Recent cholesterol treatment guidelines recommended selecting patients for statin treatment based on predicted 10-year absolute risk (AR10) of ASCVD.6,7 In addition to recommending primary prevention statin treatment for adults with diabetes and LDL-C levels of at least 190 mg/dL (to convert to millimoles per liter, multiply by 0.0259), the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline recommended statins in adults with AR10 of at least 7.5%.6 A 2018 ACC/AHA update suggested statins be considered for primary prevention in patients without diabetes and with borderline AR10 (5.0%-7.4%) if the patients have risk-enhancing factors.2 Among those risk-enhancing factors is an LDL-C level of at least 160 mg/dL.Keywords
This publication has 33 references indexed in Scilit:
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsCirculation, 2014
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance MeasuresCirculation, 2014
- What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choiceEuropean Journal of Preventive Cardiology, 2014
- Discontinuation of Statins in Routine Care SettingsAnnals of Internal Medicine, 2013
- Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin EraCirculation, 2011
- Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysisBMJ, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Cost-Effectiveness of Using High-Sensitivity C-Reactive Protein to Identify Intermediate- and Low-Cardiovascular-Risk Individuals for Statin TherapyCirculation, 2010
- Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trialsQJM: An International Journal of Medicine, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010